Pub Date : 2025-12-22DOI: 10.1016/j.clindermatol.2025.12.002
Sammya Mufarrej, Franco Rongioletti, Paolo Romanelli
Access to biologic therapies for psoriasis remains uneven among uninsured or underinsured patients, despite safety-net systems and manufacturer assistance. A retrospective cohort study examined all patients treated for psoriasis at the Psoriasis Biologics Clinic at Jackson Memorial Hospital (Miami, Florida) from January 2020 to May 2025. With no exclusions, the cohort reflected the full clinic population. The study assessed eligibility and initiation of biologics within a model combining hospital financial assistance and manufacturer support. Among 187 patients (mean age 52.7 years; 55.6% women), 67.4% were prescribed biologics. Most identified as Hispanic, with smaller African-American and non-Hispanic White groups. Adalimumab and secukinumab were the most common therapies. Insurance sources included government programs, hospital assistance, and underinsured plans. Barriers to starting biologics were reported in 15.5% of patients, mainly due to insurance denials or lapses. Nearly all patients had no copay, and those using the Jackson Financial Assistance Program received biologics at no cost. Although this safety-net model enabled most patients to access biologics, ongoing racial and insurance-related disparities indicate the need for broader structural and policy solutions to achieve durable equity in care.
{"title":"Equitable access to biologic therapies in a psoriasis safety-net clinic: A retrospective cohort study.","authors":"Sammya Mufarrej, Franco Rongioletti, Paolo Romanelli","doi":"10.1016/j.clindermatol.2025.12.002","DOIUrl":"10.1016/j.clindermatol.2025.12.002","url":null,"abstract":"<p><p>Access to biologic therapies for psoriasis remains uneven among uninsured or underinsured patients, despite safety-net systems and manufacturer assistance. A retrospective cohort study examined all patients treated for psoriasis at the Psoriasis Biologics Clinic at Jackson Memorial Hospital (Miami, Florida) from January 2020 to May 2025. With no exclusions, the cohort reflected the full clinic population. The study assessed eligibility and initiation of biologics within a model combining hospital financial assistance and manufacturer support. Among 187 patients (mean age 52.7 years; 55.6% women), 67.4% were prescribed biologics. Most identified as Hispanic, with smaller African-American and non-Hispanic White groups. Adalimumab and secukinumab were the most common therapies. Insurance sources included government programs, hospital assistance, and underinsured plans. Barriers to starting biologics were reported in 15.5% of patients, mainly due to insurance denials or lapses. Nearly all patients had no copay, and those using the Jackson Financial Assistance Program received biologics at no cost. Although this safety-net model enabled most patients to access biologics, ongoing racial and insurance-related disparities indicate the need for broader structural and policy solutions to achieve durable equity in care.</p>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.1016/j.clindermatol.2025.11.003
Julia Ross, Camilla M Lee, Timothy Klufas, Albert E Zhou, Jane M Grant-Kels
Dissemination of research findings is a crucial part of academic progress; however, many barriers to publishing in dermatology may prevent equitable researcher involvement and representation. The term "independent journal" (IJ) is not yet widely established in the academic literature. IJs refer to self-initiated and potentially self-sponsored journals. IJs are typically initiated by individual clinicians or small groups rather than well-established organizations or commercial entities and have the goal of disseminating new research ideas or filling a current gap in the literature. Although many IJs in dermatology have gained respect and contribute meaningfully to the field, there are ethical concerns regarding potential founding-sponsorship bias, peer-review protocols, and the resources used to ensure academic quality. To avoid potential ethical concerns regarding IJs' credibility, the goals of the journal and the peer-review processes should be clearly delineated. IJs offer the opportunity to make research more accessible and transform the publishing industry. Herein, we define and delineate IJs from other journals, while exploring ethical issues and directions for clinicians to consider when studying or creating journals.
{"title":"Self-made journals in dermatology: Navigating the ethical landscape of dermatologist-sponsored independent journals.","authors":"Julia Ross, Camilla M Lee, Timothy Klufas, Albert E Zhou, Jane M Grant-Kels","doi":"10.1016/j.clindermatol.2025.11.003","DOIUrl":"10.1016/j.clindermatol.2025.11.003","url":null,"abstract":"<p><p>Dissemination of research findings is a crucial part of academic progress; however, many barriers to publishing in dermatology may prevent equitable researcher involvement and representation. The term \"independent journal\" (IJ) is not yet widely established in the academic literature. IJs refer to self-initiated and potentially self-sponsored journals. IJs are typically initiated by individual clinicians or small groups rather than well-established organizations or commercial entities and have the goal of disseminating new research ideas or filling a current gap in the literature. Although many IJs in dermatology have gained respect and contribute meaningfully to the field, there are ethical concerns regarding potential founding-sponsorship bias, peer-review protocols, and the resources used to ensure academic quality. To avoid potential ethical concerns regarding IJs' credibility, the goals of the journal and the peer-review processes should be clearly delineated. IJs offer the opportunity to make research more accessible and transform the publishing industry. Herein, we define and delineate IJs from other journals, while exploring ethical issues and directions for clinicians to consider when studying or creating journals.</p>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-11DOI: 10.1016/j.clindermatol.2025.11.002
Uwe Wollina, Ayşe Serap Karadağ
Şerefeddin Sabuncuoğlu (1385 to 1468 or 1470), a physician and surgeon from Amasya in Anatolia, is the author of three major books on pharmacy, medicine, and surgery, as well as the author of the first illustrated surgical textbook in the Turkish-Islamic literature, Cerrahiyyet'ul-Haniyye (Imperial Surgery), written in Turkish. It is the first book to contain colored illustrations of surgical procedures and instruments. Sabuncuoğlu was an unpretentious, curious, and intelligent physician and surgeon, a calligrapher, and a miniature artist. Although the teachers of medicine and the surgeons in Central Anatolia used his book, it was ignored by the Ottoman scientific elite in Istanbul during his lifetime.
{"title":"Anatolian contribution to surgery and medicine in the 15th century - Şerefeddin Sabuncuoğlu.","authors":"Uwe Wollina, Ayşe Serap Karadağ","doi":"10.1016/j.clindermatol.2025.11.002","DOIUrl":"10.1016/j.clindermatol.2025.11.002","url":null,"abstract":"<p><p>Şerefeddin Sabuncuoğlu (1385 to 1468 or 1470), a physician and surgeon from Amasya in Anatolia, is the author of three major books on pharmacy, medicine, and surgery, as well as the author of the first illustrated surgical textbook in the Turkish-Islamic literature, Cerrahiyyet'ul-Haniyye (Imperial Surgery), written in Turkish. It is the first book to contain colored illustrations of surgical procedures and instruments. Sabuncuoğlu was an unpretentious, curious, and intelligent physician and surgeon, a calligrapher, and a miniature artist. Although the teachers of medicine and the surgeons in Central Anatolia used his book, it was ignored by the Ottoman scientific elite in Istanbul during his lifetime.</p>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145511927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-10-03DOI: 10.1016/j.clindermatol.2025.09.023
Sophie Walter BMed, MD, BSc(Med) (Hons)
This presentation presents the life and career of Tadeusz Stępniewski (1905-1987), a Polish dermatologist awarded the title “Righteous Among the Nations” for his bravery saving Jews during the Holocaust, collates information about other dermatologists who have also received the title and reflects on the place of virtue in the profession. Various sources were used to provide information about Stępniewski, including copies of materials held by the Archives Department of Yad Vashem, Israel’s Holocaust memorial authority. At the outbreak of World War II, Stępniewski had a private dermatology practice in central Warsaw and was affiliated with the Skin and Venereal Diseases Clinic at the University of Warsaw. During the German occupation, he assisted Jews by helping them escape from the Warsaw ghetto, hiding them in various locations, providing dermatologic care and other medical treatments, contributing to an underground medical publication, and giving financial aid. Stępniewski is one of seven dermatologists who have received the Righteous Among the Nations title. Their heroic deeds bring to the forefront the role of virtue in all aspects of the lives of dermatologists and other medical professionals.
Tadeusz Stepniewski（1905-1987）是一位波兰皮肤科医生，因其在大屠杀期间拯救犹太人的英勇行为而被授予“国际正义”称号，他的生活和职业生涯整理了其他获得该称号的皮肤科医生的信息，并反思了美德在该职业中的地位。提供关于斯特普涅夫斯基的信息使用了各种来源，包括以色列大屠杀纪念机构亚德瓦谢姆档案馆持有的材料副本。第二次世界大战爆发时，斯特普涅夫斯基在华沙市中心开了一家私人皮肤科诊所，隶属于华沙大学的皮肤和性病诊所。在德国占领期间，他帮助犹太人逃离华沙隔都，把他们藏在不同的地方，提供皮肤护理和其他医疗服务，为地下医学出版物撰稿，并提供经济援助。斯蒂芬尼夫斯基是七位获得“国际正义”称号的皮肤科医生之一。他们的英雄事迹使美德在皮肤科医生和其他医疗专业人员生活的各个方面发挥了重要作用。
{"title":"Tadeusz Stępniewski: Polish dermatologist and “Righteous Among the Nations”","authors":"Sophie Walter BMed, MD, BSc(Med) (Hons)","doi":"10.1016/j.clindermatol.2025.09.023","DOIUrl":"10.1016/j.clindermatol.2025.09.023","url":null,"abstract":"<div><div>This presentation presents the life and career of Tadeusz Stępniewski (1905-1987), a Polish dermatologist awarded the title “Righteous Among the Nations” for his bravery saving Jews during the Holocaust, collates information about other dermatologists who have also received the title and reflects on the place of virtue in the profession. Various sources were used to provide information about Stępniewski, including copies of materials held by the Archives Department of Yad Vashem, Israel’s Holocaust memorial authority. At the outbreak of World War II, Stępniewski had a private dermatology practice in central Warsaw and was affiliated with the Skin and Venereal Diseases Clinic at the University of Warsaw. During the German occupation, he assisted Jews by helping them escape from the Warsaw ghetto, hiding them in various locations, providing dermatologic care and other medical treatments, contributing to an underground medical publication, and giving financial aid. Stępniewski is one of seven dermatologists who have received the Righteous Among the Nations title. Their heroic deeds bring to the forefront the role of virtue in all aspects of the lives of dermatologists and other medical professionals.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"43 6","pages":"Pages 772-782"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-10-03DOI: 10.1016/j.clindermatol.2025.09.028
Giorgio Stabile MD , Nazario Pesce MD , Giorgia Di Marco MD , Antonio Podo Brunetti MD , Gianmarco Diego Bigotto MD , Stefania Guida MD , Franco Rongioletti MD
Mucin deposition in the skin, a hallmark feature in dermatopathology, is frequently associated with connective tissue diseases such as lupus erythematosus, dermatomyositis, and, to a lesser extent, scleroderma. Although mucin deposition commonly accompanies specific skin lesions in lupus erythematosus, dermatomyositis, and sometimes scleroderma, its occurrence as a distinct clinical manifestation with defining histopathologic features is rare. Such presentations that are classified as primary cutaneous mucinoses not only aid in diagnosis but may also have prognostic implications. This study systematically reviews the literature to evaluate case demographics, clinical characteristics, histologic findings, immunologic markers, and treatment responses of primary cutaneous mucinoses linked to connective tissue diseases. Our findings highlight that mucin deposition exhibits variable presentations and serves as a valuable diagnostic clue, particularly when integrated with other clinical and histopathologic criteria.
Mucin, a high-molecular-weight glycoprotein complex primarily composed of hyaluronic acid, is a standard component of dermal connective tissues. It is produced in small amounts by fibroblasts and mast cells and is known for its high water-holding capacity. Excessive mucin deposition, however, which can occur in certain pathologic states, leads to dermal swelling known as myxedema. Cutaneous mucinosis is often associated with connective tissue diseases, in which mucin deposition can serve as histologic evidence for conditions such as lupus erythematosus (LE) or dermatomyositis (DM), particularly in the appropriate clinical context. Less frequently, mucin is also observed in scleroderma cases.1,2 Although mucin deposition can accompany specific skin lesions in LE and DM, cases in which it is a prominent and defining histopathologic feature are rare. Such cases classified into the chapter of primary cutaneous mucinoses have diagnostic value and may also serve as prognostic indicators. This review assesses the diagnostic and prognostic significance of primary cutaneous mucinoses associated with connective tissue diseases.
{"title":"Primary cutaneous mucinoses in connective tissue diseases as a diagnostic and prognostic challenge","authors":"Giorgio Stabile MD , Nazario Pesce MD , Giorgia Di Marco MD , Antonio Podo Brunetti MD , Gianmarco Diego Bigotto MD , Stefania Guida MD , Franco Rongioletti MD","doi":"10.1016/j.clindermatol.2025.09.028","DOIUrl":"10.1016/j.clindermatol.2025.09.028","url":null,"abstract":"<div><div>Mucin deposition in the skin, a hallmark feature in dermatopathology, is frequently associated with connective tissue diseases such as lupus erythematosus, dermatomyositis, and, to a lesser extent, scleroderma. Although mucin deposition commonly accompanies specific skin lesions in lupus erythematosus, dermatomyositis, and sometimes scleroderma, its occurrence as a distinct clinical manifestation with defining histopathologic features is rare. Such presentations that are classified as primary cutaneous mucinoses not only aid in diagnosis but may also have prognostic implications. This study systematically reviews the literature to evaluate case demographics, clinical characteristics, histologic findings, immunologic markers, and treatment responses of primary cutaneous mucinoses linked to connective tissue diseases. Our findings highlight that mucin deposition exhibits variable presentations and serves as a valuable diagnostic clue, particularly when integrated with other clinical and histopathologic criteria.</div><div>Mucin, a high-molecular-weight glycoprotein complex primarily composed of hyaluronic acid, is a standard component of dermal connective tissues. It is produced in small amounts by fibroblasts and mast cells and is known for its high water-holding capacity. Excessive mucin deposition, however, which can occur in certain pathologic states, leads to dermal swelling known as myxedema. Cutaneous mucinosis is often associated with connective tissue diseases, in which mucin deposition can serve as histologic evidence for conditions such as lupus erythematosus (LE) or dermatomyositis (DM), particularly in the appropriate clinical context. Less frequently, mucin is also observed in scleroderma cases.<span><span><sup>1</sup></span></span><sup>,</sup><span><span><sup>2</sup></span></span> Although mucin deposition can accompany specific skin lesions in LE and DM, cases in which it is a prominent and defining histopathologic feature are rare. Such cases classified into the chapter of primary cutaneous mucinoses have diagnostic value and may also serve as prognostic indicators. This review assesses the diagnostic and prognostic significance of primary cutaneous mucinoses associated with connective tissue diseases.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"43 6","pages":"Pages 810-827"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-08-26DOI: 10.1016/j.clindermatol.2025.08.002
Waseem Hassan PhD , Fred Paas PhD
Assessing academic performance in dermatology is an interesting and evolving challenge. Early-career researchers often look for clear indicators to identify leading authors; however, reliance on single measures such as citation counts or the h-index provides only a limited view of scholarly influence. Using diverse bibliometric indicators from Scopus, we observed that author rankings shifted considerably depending on the metric applied, reflecting the lack of agreement on how best to capture academic impact. Similarly, we noted that ethical publications (letters, notes, and related formats) in dermatology may contribute to scholarly discussions and institutional practices but often receive modest citation profiles, highlighting the gap between measurable indicators and genuine value. Inflated authorship practices and citation manipulation further complicate fair evaluation. Fractional authorship models and multidimensional frameworks that consider publication type, journal quality, collaboration, funding strength, and broader societal contributions may offer more balanced perspectives. We suggest that institutions, journals, and training programs promote the ethical use of metrics and integrate qualitative assessments alongside quantitative ones. Such an approach can foster fairness, transparency, and meaningful recognition within dermatology and academic medicine more broadly.
{"title":"Rethinking research metrics in dermatology and beyond","authors":"Waseem Hassan PhD , Fred Paas PhD","doi":"10.1016/j.clindermatol.2025.08.002","DOIUrl":"10.1016/j.clindermatol.2025.08.002","url":null,"abstract":"<div><div>Assessing academic performance in dermatology is an interesting and evolving challenge. Early-career researchers often look for clear indicators to identify leading authors; however, reliance on single measures such as citation counts or the h-index provides only a limited view of scholarly influence. Using diverse bibliometric indicators from Scopus, we observed that author rankings shifted considerably depending on the metric applied, reflecting the lack of agreement on how best to capture academic impact. Similarly, we noted that ethical publications (letters, notes, and related formats) in dermatology may contribute to scholarly discussions and institutional practices but often receive modest citation profiles, highlighting the gap between measurable indicators and genuine value. Inflated authorship practices and citation manipulation further complicate fair evaluation. Fractional authorship models and multidimensional frameworks that consider publication type, journal quality, collaboration, funding strength, and broader societal contributions may offer more balanced perspectives. We suggest that institutions, journals, and training programs promote the ethical use of metrics and integrate qualitative assessments alongside quantitative ones. Such an approach can foster fairness, transparency, and meaningful recognition within dermatology and academic medicine more broadly.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"43 6","pages":"Pages 865-867"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-10-03DOI: 10.1016/j.clindermatol.2025.09.021
Carla Stephan MD , Cynthia Magro MD
Olaparib is a polyadenosine diphosphate–ribose polymerase (PARP) inhibitor that is used in the treatment of advanced ovarian cancer. PARP inhibitors result in the accumulation of single-strand DNA breaks that are toxic to tumor cells. PARP inhibition with a concomitant Breast cancer susceptibility gene (BRCA) mutation results in what is known as synthetic lethality to the tumor cells. Cutaneous adverse effects have been reported with PARP inhibition, namely pruritus, photosensitivity reactions, edema, vasculitis, and panniculitis. We present a case of a 36-year-old woman who developed dermatitis on the bilateral lower extremities one month after starting olaparib for advanced ovarian carcinoma. A punch biopsy taken from the eruption was consistent with a lymphocytic and granulomatous small-vessel vasculitis with a component of lobular panniculitis. The exact pathogenic mechanism of vasculitis and panniculitis in the setting of a PARP inhibitor is unclear. Given the multiple functions of PARP at the cellular level, it is not surprising that the inhibition of this superfamily may result in adverse effects. In particular, the inhibition of PARP has been shown to alter the inflammatory milieu from a Th2 predominance to a Th1 predominance. This shift in polarization may play a role in the development of vasculitis and panniculitis in such patients.
{"title":"Lymphocytic and granulomatous cutaneous small-vessel vasculitis after polyadenosine diphosphate–ribose polymerase inhibitor therapy","authors":"Carla Stephan MD , Cynthia Magro MD","doi":"10.1016/j.clindermatol.2025.09.021","DOIUrl":"10.1016/j.clindermatol.2025.09.021","url":null,"abstract":"<div><div>Olaparib is a polyadenosine diphosphate–ribose polymerase (PARP) inhibitor that is used in the treatment of advanced ovarian cancer. PARP inhibitors result in the accumulation of single-strand DNA breaks that are toxic to tumor cells. PARP inhibition with a concomitant Breast cancer susceptibility gene (BRCA) mutation results in what is known as synthetic lethality to the tumor cells. Cutaneous adverse effects have been reported with PARP inhibition, namely pruritus, photosensitivity reactions, edema, vasculitis, and panniculitis. We present a case of a 36-year-old woman who developed dermatitis on the bilateral lower extremities one month after starting olaparib for advanced ovarian carcinoma. A punch biopsy taken from the eruption was consistent with a lymphocytic and granulomatous small-vessel vasculitis with a component of lobular panniculitis. The exact pathogenic mechanism of vasculitis and panniculitis in the setting of a PARP inhibitor is unclear. Given the multiple functions of PARP at the cellular level, it is not surprising that the inhibition of this superfamily may result in adverse effects. In particular, the inhibition of PARP has been shown to alter the inflammatory milieu from a Th2 predominance to a Th1 predominance. This shift in polarization may play a role in the development of vasculitis and panniculitis in such patients.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"43 6","pages":"Pages 762-765"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-08-05DOI: 10.1016/j.clindermatol.2025.07.008
Uwe Wollina MD , Leonard J. Hoenig MD , Lawrence Charles Parish MD, MD (Hon), FRCP (Edin)
This contribution provides a note on the early days of gender reassignment surgery, which was pioneered by Felix Abraham, Erwin Gohrbrandt, Ludwig Levy-Lenz, and Kurt Warnekros need dates during the 1920s. Their experimental surgeries would gain significant attention through the mass media. Such reassignment surgery has been illustrated by the life and death of Danish painter Einar Wegener (1882-1931), who underwent several gender reassignment surgeries. The narratives of his life are discussed with the views of medical progress made from the early 20th century until now.
{"title":"Early history of gender reassignment surgery in Prussia and Saxony","authors":"Uwe Wollina MD , Leonard J. Hoenig MD , Lawrence Charles Parish MD, MD (Hon), FRCP (Edin)","doi":"10.1016/j.clindermatol.2025.07.008","DOIUrl":"10.1016/j.clindermatol.2025.07.008","url":null,"abstract":"<div><div>This contribution provides a note on the early days of gender reassignment surgery, which was pioneered by Felix Abraham, Erwin Gohrbrandt, Ludwig Levy-Lenz, and Kurt Warnekros need dates during the 1920s. Their experimental surgeries would gain significant attention through the mass media. Such reassignment surgery has been illustrated by the life and death of Danish painter Einar Wegener (1882-1931), who underwent several gender reassignment surgeries. The narratives of his life are discussed with the views of medical progress made from the early 20th century until now.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"43 6","pages":"Pages 879-884"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-10-01DOI: 10.1016/j.clindermatol.2025.09.022
Uwe Wollina MD , Leonard J. Hoenig MD , Lawrence Charles Parish MD, MD (Hon), FRCP (Edin)
Religion has long served as a means to avoid disease and death or to come to terms with the inevitable. Patron saints to protect against disease and to offer a miraculous cure have been adopted in the Christian world since medieval times. The invocation of saints in need and danger is one of the most intrinsic, traditional characteristics of popular piety. More than 14 saints are known as patrons of those who suffer from skin and venereal diseases. We provide an overview of several major saints with a connection to dermatology. Although women were not uncommon among the healers of the period, women saints are very rare, reflecting the traditional medieval patriarchal order.
{"title":"A collection of saints for sufferers of skin diseases","authors":"Uwe Wollina MD , Leonard J. Hoenig MD , Lawrence Charles Parish MD, MD (Hon), FRCP (Edin)","doi":"10.1016/j.clindermatol.2025.09.022","DOIUrl":"10.1016/j.clindermatol.2025.09.022","url":null,"abstract":"<div><div>Religion has long served as a means to avoid disease and death or to come to terms with the inevitable. Patron saints to protect against disease and to offer a miraculous cure have been adopted in the Christian world since medieval times. The invocation of saints in need and danger is one of the most intrinsic, traditional characteristics of popular piety. More than 14 saints are known as patrons of those who suffer from skin and venereal diseases. We provide an overview of several major saints with a connection to dermatology. Although women were not uncommon among the healers of the period, women saints are very rare, reflecting the traditional medieval patriarchal order.</div></div>","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"43 6","pages":"Pages 766-771"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on “Beyond beauty: Neurocosmetics, the skin-brain axis, and the future of emotionally intelligent skincare”","authors":"S. Dhanya Dedeepya MD, Vaishali Goel PhD, Nivedita Nikhil Desai MD","doi":"10.1016/j.clindermatol.2025.10.001","DOIUrl":"10.1016/j.clindermatol.2025.10.001","url":null,"abstract":"","PeriodicalId":10358,"journal":{"name":"Clinics in dermatology","volume":"43 6","pages":"Pages 871-872"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号